Cargando…

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer in the United States. Immunotherapies and cytotoxic chemotherapies used to treat advanced NSCLC carry a substantial risk of adverse events (AEs), but real-world data on the incidence and costs associated with the u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engel-Nitz, Nicole M., Johnson, Michael P., Bunner, Scott H., Ryan, Kellie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391087/ https://www.ncbi.nlm.nih.gov/pubmed/32463768 http://dx.doi.org/10.18553/jmcp.2020.26.6.729

Ejemplares similares

Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy
por: Bullock, Andrea, et al.
Publicado: (2020)

The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
por: Anton, Angelyn, et al.
Publicado: (2021)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
por: Lu, Jinmiao, et al.
Publicado: (2022)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Porta, C
Publicado: (2010)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
por: Isla, Dolores, et al.
Publicado: (2016)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
por: Chowdhury, Simon, et al.
Publicado: (2020)

Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
por: Obinata, Daisuke, et al.
Publicado: (2022)

Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
por: Faoro, Lisa, et al.
Publicado: (2023)

A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
por: Byeon, Seonggyu, et al.
Publicado: (2016)

A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study
por: Guo, Yanan, et al.
Publicado: (2020)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry
por: Galli, Luca, et al.
Publicado: (2022)

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
por: Barzi, Afsaneh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_edjp3oiklg8ecjpur9mm3gkku2